Cobra Biologics, an international CDMO of biologics and pharmaceuticals, has been contracted to develop a second cell line for Alligator Bioscience AB, a Swedish biotechnology company. Alligator has requested further support from the team at Cobra to develop the cell line for production of new drug candidate ADC-1015, a bispecific immune activator developed to induce superior immune activation. Cobra is using their expression system maxXpress, along with a historically documented master cell ...